VANDA PHARMACEUTICALS INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
VANDA PHARMACEUTICALS INC. (VNDA) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $6.77 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $6.77M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $7.28M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $7.34M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $5.07M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $6.77M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.28M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $7.34M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $5.07M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $5.24M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $4.83M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $4.94M 10-K · filed 2026-02-12 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |